33.05MMarket Cap-700P/E (TTM)
0.710High0.450Low4.10MVolume0.455Open0.454Pre Close2.50MTurnover9.07%Turnover RatioLossP/E (Static)48.64MShares3.24952wk High1.53P/B30.76MFloat Cap0.45052wk Low--Dividend TTM45.28MShs Float31.690Historical High--Div YieldTTM57.21%Amplitude0.450Historical Low0.610Avg Price1Lot Size
Cue Biopharma Stock Forum
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma (CUE.US)$
No comment yet